India's Biosimilar Norms: Patient Safety Debate Boils Over
Executive Summary
A recent panel discussion in India brought to the fore simmering tensions over the country's guidelines on biosimilars, with some panelists suggesting the guidelines compromise on patient safety while other experts sought to tone down any alarmist conclusions.
You may also be interested in...
Here’s What Competition Looks Like In India’s Humira Biosimilars Market
Competition may be just readying to jump in and gnaw into Humira’s share in Europe later this year, but the Indian market for biosimilar adalimumab already has more than half a dozen players, with distinct pricing characteristics. Scrip takes a peek into the competitive market.
Here’s What Competition Looks Like In India’s Humira Biosimilars Market
Competition may be just readying to jump in and gnaw into Humira’s share in Europe later this year, but the Indian market for biosimilar adalimumab already has more than half a dozen players, with distinct pricing characteristics. Scrip takes a peek into the competitive market.
Biocon: Japan Biosimilar Glargine Nod To Open Other Doors
India's largest biopharmaceutical company, Biocon, has reported quarterly net profit rocketed nearly 80% thanks to exceptional income, and says Japan's regulatory nod for its insulin glargine should help “fast-track” approvals of the biosimilar in both emerging markets and advanced economies.